These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18157009

  • 1. Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma.
    Zhu Y, Tibensky I, Schmidt J, Hackert T, Ryschich E, Jäger D, Büchler MW, Märten A.
    J Immunother; 2008 Jan; 31(1):28-33. PubMed ID: 18157009
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy of interferon-alpha and 5-fluorouracil inhibits tumor angiogenesis in human hepatocellular carcinoma cells by regulating vascular endothelial growth factor and angiopoietins.
    Wada H, Nagano H, Yamamoto H, Arai I, Ota H, Nakamura M, Damdinsuren B, Noda T, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Doki Y, Dono K, Nakamori S, Sakon M, Monden M.
    Oncol Rep; 2007 Oct; 18(4):801-9. PubMed ID: 17786339
    [Abstract] [Full Text] [Related]

  • 3. Combinational therapy of interferon-α and chemotherapy normalizes tumor vasculature by regulating pericytes including the novel marker RGS5 in melanoma.
    Liu P, Zhang C, Chen J, Zhang R, Ren J, Huang Y, Zhu F, Li Z, Wu G.
    J Immunother; 2011 Apr; 34(3):320-6. PubMed ID: 21389866
    [Abstract] [Full Text] [Related]

  • 4. Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma.
    Zhu Y, Tibensky I, Schmidt J, Ryschich E, Märten A.
    J Immunother; 2008 Sep; 31(7):599-606. PubMed ID: 18600184
    [Abstract] [Full Text] [Related]

  • 5. Combination therapy of human pancreatic cancer implanted in nude mice by oral fluoropyrimidine anticancer agent (S-1) with interferon-alpha.
    Miyake K, Tsuchida K, Sugino H, Imura S, Morine Y, Fujii M, Shimada M.
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):113-26. PubMed ID: 16699793
    [Abstract] [Full Text] [Related]

  • 6. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts.
    Bockhorn M, Tsuzuki Y, Xu L, Frilling A, Broelsch CE, Fukumura D.
    Clin Cancer Res; 2003 Sep 15; 9(11):4221-6. PubMed ID: 14519649
    [Abstract] [Full Text] [Related]

  • 7. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines.
    Fukasawa M, Korc M.
    Clin Cancer Res; 2004 May 15; 10(10):3327-32. PubMed ID: 15161686
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.
    Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K.
    Cancer; 2007 Dec 15; 110(12):2682-90. PubMed ID: 17973266
    [Abstract] [Full Text] [Related]

  • 10. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts.
    Holloway SE, Beck AW, Shivakumar L, Shih J, Fleming JB, Brekken RA.
    Ann Surg Oncol; 2006 Aug 15; 13(8):1145-55. PubMed ID: 16791450
    [Abstract] [Full Text] [Related]

  • 11. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
    Landen CN, Lu C, Han LY, Coffman KT, Bruckheimer E, Halder J, Mangala LS, Merritt WM, Lin YG, Gao C, Schmandt R, Kamat AA, Li Y, Thaker P, Gershenson DM, Parikh NU, Gallick GE, Kinch MS, Sood AK.
    J Natl Cancer Inst; 2006 Nov 01; 98(21):1558-70. PubMed ID: 17077358
    [Abstract] [Full Text] [Related]

  • 13. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K, Yoshii J, Namisaki T, Yamazaki M, Asada K, Tsujimoto T, Akahane T, Uemura M, Fukui H.
    Oncol Rep; 2007 Feb 01; 17(2):441-6. PubMed ID: 17203185
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis.
    von Marschall Z, Scholz A, Cramer T, Schäfer G, Schirner M, Oberg K, Wiedenmann B, Höcker M, Rosewicz S.
    J Natl Cancer Inst; 2003 Mar 19; 95(6):437-48. PubMed ID: 12644537
    [Abstract] [Full Text] [Related]

  • 17. The up-regulation of type I interferon receptor gene plays a key role in hepatocellular carcinoma cells in the synergistic antiproliferative effect by 5-fluorouracil and interferon-alpha.
    Oie S, Ono M, Yano H, Maruyama Y, Terada T, Yamada Y, Ueno T, Kojiro M, Hirano K, Kuwano M.
    Int J Oncol; 2006 Dec 19; 29(6):1469-78. PubMed ID: 17088986
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.
    Scholz A, Wagner K, Welzel M, Remlinger F, Wiedenmann B, Siemeister G, Rosewicz S, Detjen KM.
    Gut; 2009 Feb 19; 58(2):261-70. PubMed ID: 18829975
    [Abstract] [Full Text] [Related]

  • 20. Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo.
    Kojiro S, Yano H, Ogasawara S, Momosaki S, Takemoto Y, Nishida N, Kojiro M.
    J Gastroenterol Hepatol; 2006 Jan 19; 21(1 Pt 1):129-37. PubMed ID: 16706824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.